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Abstract
The paper gives a short system engineering review on the treatment of diabetes covering control 
engineering and mathematical modeling issues. The Artificial Pancreas (AP) concept is discussed 
together with the Intensive Care (ICU) idea for automatic treatment of diabetic patients. This highly 
interdisciplinary concept involves beyond medical sciences, control engineering and biomedical 
engineering knowledge. Having already developed continuous glucose sensor devices and highly 
performant insulin pumps, the automatic control concept could be an efficient solution for millions of 
people living with diabetes for accurate metabolic conditions management.
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Introduction
Diabetes Mellitus (DM) or shortly diabetes is used as the 
collective name of several chronic metabolic diseases of the 
human body where by impaired insulin production the human 
body cannot automatically regulate the glucose level [1,2]. 
Different types of DM exist associated with diverse symptoms
and side effects. The main types are the following [3]: 
1) Type 1 or insulin-dependent DM (T1DM);
2) Type 2 or insulin-independent DM (T2DM);
3) Gestational DM (GDM);
4) Double DM (DDM);
5) Genetic related DM (GrDM);
6) Other types of DM which can be induced by different kind of 
diseases, drugs, chemicals and cancers [3]. 
Type 1 and type 2 cover more than 95% of the cases, T1DM being 
more critical. T1DM is an autoimmune disease, which mainly appears 
in young age and its general medical symptom can be described by 
the fact that the immune system of human body automatically 
destroys the beta-cells responsible for insulin production. As a result, 
in case of T1DM the patient needs immediate insulin treatment to 
avoid the metabolic breakdown, which starts with hypoglycemic and 
ketoacidotic state and ends with the death of the patient [2,4]. This is 
the fact why T1DM is known as insulin dependent DM.
T2DM is the ’Civilization Disease’ form of DM as it is largely 
related to the wrong or not appropriate nourishment [5]. T2DM is a 
self-generating process which appears after long term hyperglycemia 
slowly increasing insulin insensitivity during the years. No insulin 
injection is needed at the beginning of this type of DM, but in its 
final un- or poorly-treated stage it needs continuous external insulin 
treatment to handle the level of glycemia [6, 7]. In case of DDM the 
worst effects of T1DM and T2DM prevail, namely, the autoimmune 
effects are coupled with increasing insulin resistance. This type of 
DM has upward prevalence in the recent years, which caused by 
the double metabolic stress comes from genetic predisposition and 
lifestyle [8-10].
GDM occurs during pregnancy and most of the cases the DM state 
ends with the birth, however, those women who suffer from GDM 
particularly are inclined to emergence of other type of DM in their 
later life [11, 12]. Genetic and the other types of DM can be caused by 
several disorders [3]. Unfortunately, the occurrence of DM shows an 
increasing trend. According to the World Health Organization’s study 
diabetic population will be doubled from 2000 to 2030 exceeding 366
*Corresponding Author: Dr. Levente Kov´acs, John von Neumann, 
Faculty of Informatics, University Research and Innovation Center, 
Physiological Controls Group, Obuda University, Budapest, Hungary; E-mail: 
kovacs.levente@nik.uni-obuda.hu
Citation: Kov´acs L, Eigner G (2015) System Engineering Approach of Diabetes 
Treatment. Int J Diabetes Clin Diagn  3: 116. doi: http://dx.doi.org/10.15344/2394-
1499/2016/116
Copyright: © 2015 Kov´acs et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited.
million people [13]. Newer studies have reported that this number 
is already exceeded and the total count of the diabetic population 
was around 382 million in 2013, worldwide. Moreover, the projected 
number of diagnosed and undiagnosed DM cases is going to reach 
592 million in 2035 which is the 4.8-6.1% of the estimated total 
human population on Earth [1,14].
Although DM is still incurable, the therapy of DM presented 
considerable progression in the recent years, for instance the 
appearance of different cell stimulating drugs [7,15], partial 
immunosuppressant drug applications in order to reduce the 
autoimmune effect [16], transplantation of Langerhansislets [17] or 
pancreas [18] and stem cell experiments [17] are just some of the 
achieved results.
The regular treatment for a diabetic patient on insulin treatment is 
based on external insulin injections. There are two main directions for 
the insulin administration:
•	 Insulin administration with insulin pens, which represents the 
ordinary, conservative therapy;
•	 Insulin administration with insulin pumps, which is a highly 
developed electromechanical device.
Both methods have the same purposes from a diabetic patient point 
of view: keeping the blood sugar level in a narrow, normoglycemic 
range (3.9-6 mmol/L or 70-110 mg/dL). An important part of these 
therapies relies on reaching different quality requirements, like 
body weight, level of physical activation and levels of physiological 
markers. The main difference is the way how these requirements 
are achieved. By the appearance of the insulin pump therapy the 
automated treatment possibility of diabetic patients has created 
known as the Artificial Pancreas (AP) concept. AP represents today 
the most challenging engineering tool in the treatment of DM [19]. In 
the following section, we summarize the AP concept, realization tools 
and devices, and the engineering considerations behind.
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Discussion
The concept of Artificial Pancreas In order to realize an AP three 
necessary subparts is needed [19-21]:
1. An insulin pump that stores and injects the rapid acting insulin;
2. A Continuous Glucose Monitoring System (CGMS) for 
continuous blood sugar level measurement;
3. Appropriate software components including control algorithms, 
user interfaces, drivers.
Several insulin pumps are available on the global market [22-24] 
with different solutions. The basic concept is an ’All-in-One’ type 
device, where the hardware, mechanical and software subparts are 
integrated into one device [25]. The other conceptual realization is 
the divided solution, where important subsystems like the control 
algorithm or raw data processing are running on an additional device 
[26, 27]. The insulin pump contains an insulin cartridge, a Graphical 
User Interface (GUI), the battery and the necessary mechanical and 
hardware elements to inject the insulin and to operate the device. 
The CGMS system is used in parallel with the insulin pump. The 
operations of CGMS are based on various principles.
In practice, the most widely used systems are external devices fixed 
on the abdominal skin surface and connected to the subcutaneous 
level through a thin catheter. The most frequent measuring principles 
are enzymatic based (Glucose Oxidase (GOx)). Beside its several 
benefits CGMS has also some disadvantages mostly from control 
engineering point of view: sensors measurements are done only every 
5 minutes. Implantable CMGS have been also appeared, but these are 
not available on the market, yet [28].
As mentioned above, the third necessary component to realize 
the AP is the appropriate software elements, including the control 
algorithms, the  ”soul” of this approach. Figure 1 shows the schematic 
representation of the AP concept.
Control Algorithms for AP
Due to the fact that insulin pump therapies are used mostly in 
case of T1DM, the advanced control algorithms developed inside AP 
researches focus on this DM form. The main expectation from an AP 
control algorithm is the automatic glucose regulation in order to keep 
the blood glucose concentration in the normal glycemic range, i.e. 70-
110 mg/dL (3.9-6 mmol/L) and relying if possible on the compliance 
of the patient. The ultimate goal is to avoid the dangerously low blood 
glucose levels (massive hypoglycemia) that could directly endanger 
the patients’ life.
As DM is a widely researched area of biomedical engineering, 
almost every control method can be found in the literature. The most 
important directions focus on model predictive control” (MPC), 
fuzzy rule-based, classical PID control or robust control techniques; 
however, without having yet a general solution on the problem [19-21]. 
Simplistically, every control algorithm considers similar principles; 
namely, the fulfillment of prescribed quality and quantity properties. 
The first attempts on this area were related to ”Proportional-Integral-
Derivative (PID)” control being still the most widely used classical 
control technique in the industry. Although the basic concept of 
PID control is not too sophisticated, highly advanced solutions like 
robust PID [30, 31] or switching PID [32] have been applied for the 
AP concept.
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MPC techniques represent probably the mostly used advanced 
control method in the AP concept, but they suffer from intra- and 
inter-patient variability and external noises. MPC is a model based 
solution meaning that the controller tuning is based on the properties 
of a mathematical model (called nominal model). Nonetheless, 
MPC algorithms produce the best results in individual therapy with 
considering closely ideal conditions. Several, highly developed MPC 
based control solutions appeared in the recent years like Robust 
MPC (RMPC), Nonlinear MPC (NMPC), Robust, Nonlinear MPC 
(RNMPC), MPC with moving horizon [33-36].
Soft computing methodologies have been applied also several times 
in the AP concept, but only in the recent years have been investigated 
in clinical trials [37-39]. Modern robust control methods like L2- or 
H∞-based ones were introduced in the AP researches in order to 
stave off the determinative uncertainties coming from inter- and intra 
patient variability. Supplemented by Linear Parameter Variability 
(LPV) methodology (providing the opportunity to handle the original 
nonlinear system/model as a linear one; hence, to give access using 
the original nonlinear model for linear control methods enumerated 
above), modern robust control successfully deals with the quality and 
quantity requirements [40-43].
 
Another useful direction in this domain proved to be the 
combination of LPV methodologies with Linear Matrix Inequalities 
(LMI)-based one [44], [45]. Its newest direction is connected to Tensor 
Product (TP) transformations based LMI controller design that is not 
validated yet in AP, but it can be useful in control of physiological 
systems [46-48].
Dual hormone controllers consider beside the insulin the glucagon 
hormone as well; hence, it represents another conceptual control 
approach in AP researches [49]. Clinical trials also starred in this 
direction with encouraging results [50].
Evolution of modeling aspects of diabetes from control perspectives
Controller design applications require a valid mathematical 
description of the physiological process of glucose-insulin interaction 
reflected in a mathematical model. The main considerations in the 
modeling of DM respect to the AP concept are briefly summarized 
in this section.
Figure 1: General concept of the AP[29].
Figure-2 emphasizes the key elements to be accounted during 
modeling and controller development. The modeling of diabetes 
started with patient models having today highly advanced models 
available [20].
The directions in this sense can be structured in two parts: inpatient 
and outpatient therapies. The goals of such models are different, since 
the circumstances and the environment of the patient are different. 
The followings give a short review on the evolution of the modeling 
parts developed from control theoretical perspectives.
Inpatient therapies mostly connect to Intensive Care Unit (ICU), 
where the strategy is to use as simple patient models as possible. As 
the patient’s environment is controlled by qualified medical staff and 
exact protocols, precise glycemic control is possible with prediction of 
the future condition of the patient as well. In the outpatient concept 
the patient requires complementary aspects as well, since physiological 
considerations to be taken into account are more complex then the 
ICU case; hence, the main expectation from an AP is an efficient 
control of the glycemic level with uncertain or sometimes unknown/
unrecorded events from the patient.
 
As a result, in parallel with the patient models additional models 
were included in the modeling loop in order to give more precised 
and more realistic physiological (models of digestion, absorption, 
β-cell, etc.) and physical (models of devices, sensors, etc.) processes.
The minimal model
As previously mentioned, the first models in the field of AP 
researches were connected to individual patient models. Their 
most important example is the Minimal Model (MM) developed by 
Bergman et al. [51-54]. Several extension of the MM were born in the 
last decades, however, the key concept remained the same in every 
case. One of these is the following modification [19]:
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The model stands from two main parts: the first two equations 
describe the glucose disappearance, while the third one is for the 
insulin kinetics. The main idea behind is that the patient gets glucose 
through p(t) [mg/min] meal absorption rate and the other input 
is the external insulin injection, u(t)  [mU/min]. After a meal the 
absorbed glucose gets into the blood stream; hence, the blood glucose 
(BG) level, G(t) [mg=dL] is increasing. If G(t) is different than the 
pancreatic target glycaemia h [mg=dL], then the β -cells injects insulin 
to the blood. However, in case of T1DM (γ = 0) where these cells were 
burned out, the only insulin source is the external injection, u(t) 
[mU=min]. The connection between glucose and insulin dynamics is 
the rate of glucose disappearance, X(t) [min-1], which is higher if the 
level of insulin is increasing. Over the year’s lot of patient models were 
derived from the MM.
The ICU models
The ICU models maintain the MM structure, but in a more 
sophisticated way. The state variables are usually kept in low level 
ranges while taking into account important kinematic (e.g. decay 
velocity, diffusion) and physiological (e.g. glucose production of the 
liver) issues. Important representatives of such kind of models are the 
Canter bury models [55-60]. However, other models appeared as well 
[21].
Outpatient models
 The outpatient models developed for the AP concept consider 
several physiological constraints and effects: the insulin dependent 
glucose consumption of the tissues whom main energy source is the 
glucose like muscles; the insulin independent glucose consumption
Figure 2: Summary of the modeling questions of the AP concept. 
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of the nervous system; continuous glucose production of the liver 
(via the glycogenesis-glycolysis); absorption, diffusion, clearance and 
decay of the insulin and glucose; the effects of the insulin, etc. Most 
of these AP models are valid for T1DM due to its general symptom, 
the total lack of internal insulin production, and operate with high 
number (6-10) of state variables. One widely used model family was 
developed by Padova- Virginia group [19,20,61,62]. Based on their 
researches they created an FDA-approved diabetes simulator as well 
[63]. Another highly developed solution was created at Cambridge, 
UK [64,65]. A more complex advanced patient model was published 
at the MIT Boston USA [66], with more than twenty state variables. 
Although these models are highly developed, they do not provide 
solutions to other types of diabetes.
Model extension to the type 2 diabetes case
Based on the diabetic status of the patient modeling and control 
considerations occurring in T1DM can be used in the therapy of 
T2DM patients as well. However, mathematical modeling of T2DM 
is not a trivial question, since the internal insulin production of the 
body should be taken into account. Furthermore, it is really hard 
to identify the diabetic status of the patient. Initially, the insulin 
production can be really high over years (to compensate the high BG 
level); nevertheless, with the progression of the disease the insulin 
production is decreasing and finally, cease with the burnout of the 
β - cells. Moreover, high inter- and intra-patient variability can be 
occurred in the amount of the produced insulin because of several 
environmental causes. Important issue represents the discontinuous 
secretion of insulin, having rather a pulsatile nature hard to model 
[67]. That is the reason why only in the recent years T2DM models 
appeared [45,68-70]. Double diabetic state and the pulsatile nature of 
internal insulin production was also successfully modeled [70]. The 
models can be even more precise if the β -cells are also taken into 
consideration [71].
Model extension to the type 2 diabetes case
Digestion and absorption models can be essential parts of a patient 
model as the effects caused by these physiological processes affect 
directly the variation of the BG level. Digestion models contain more 
details (i.e. more state variables, considered effects, etc.) as they should 
describe the whole nutrition procedure (from the meal boluses to the 
glucose absorption into the blood). Absorption models are simpler 
because they describe the way of the glucose from the gastrointestinal 
system into the blood. Usually these kinds of models are focusing only 
to the carbohydrate (CHO) intake. Highly advanced digestion model 
was developed by Andreassen et al. [72,73], considering not just the 
CHO, but also complex meal intakes. The model of De Gaetano et 
al. [74] and Dalla Man et al. [61,75,76] considered only the CHO 
intake; however, the model structures are easier to be connected to 
the AP models having high precision as well. 6) Sensor models: The 
subcutaneous glucose route and its dynamics represents an important 
question in the glucose modeling as well, since the commercially 
available CGMS devices measure interstitial fluid glucose level and 
use a mathematical model or algorithm to calculate the most likely 
BG level [77]. Usually the diffusion model is embedded into the 
patient model [61,64], but it can be placed into the sensor model 
as well [78, 79]. Simple compartmental models are also useful for 
this aspect of the AP concept [80]. In most of the cases, noise and 
disturbance models are implemented directly in the above mentioned 
models. White noise is the basic noise type using with patient and 
sensor models, while the aging effects of enzymatic based sensors
are always treated as disturbances. Finally, regarding validation and 
testing the importance of the feeding protocol should be emphasized. 
Due to the fact that the developed solutions should be tested in 
realistic circumstances, randomized feeding protocols are used. That 
means that the time frames, amounts and composition of the meal 
intakes vary during the simulation time.
Conclusion
Diabetes Mellitus is an incurable, but treatable disease. For diabetic 
patients AP could represent probably the most performant solution 
maintaining their condition in an automatically controlled way. The 
paper gave an overview of the AP concept, devices, models and the 
control engineering issues. The clinical trials started in the last years in 
the AP researches place the concept very close to market applicability 
and hence to a reality. 
Acknowledgment
Levente Kov´acs is supported by the J´anos Bolyai Research 
Scholarship of the Hungarian Academy of Sciences. Gy¨orgy Eigner 
thankfully acknowledges the support of the Robotics Special College 
of the Obuda University. The research was also supported by the 
Research and Innovation Center of the Obuda University.
References
1. I. D. Federation (2013) IDF Diabetes Atlas, 6th ed. Brussel, Belgium: 
International Diabetes Federation.
2. Fony´o A, Ligeti E (2008) Physiology (in Hungarian), 3rd ed. Budapest, 
Hungary: Medicina.
3. American Diabetes Association (2011) Diagnosis and classification of 
diabetes mellitus, Diabetes Care. 34: S5-S10.
4. National Institute of Health and Care Execellence (2015) Type 1 diabetes in 
adults: diagnosis and management. London, UK: NICE.
5. Pollan M (2009) In Defense of Food: An Eater’s Manifesto. 1st ed. London, 
UK: Penguin Press.
6. National Collaborating Centre for Chronic Conditions (2014) Type 2 
Diabetes. London, UK: Royal College of Physicians.
7. Tripathy B, Chandalia H, Das A, Rao P, Madhu S, et al. (2008) Robust 
Control and Linear Parameter Varying Approaches, Application to Vehicle 
Dynamics, 2nd ed. New Delhi, India: Jaypee Brothers Medical Publishers.
8. Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR (2013) Insulin 
resistance in type 1 diabetes: what is 'double diabetes' and what are the 
risks? Diabetologia 56: 1462-1470.
9. Libman IM, Becker DJ (2003) Coexistence of type 1 and type 2 diabetes 
mellitus: "double" diabetes? Pediatr Diabetes 4: 110-113.
10. Pozzilli P, Guglielmi C, Caprio S, Buzzetti R (2011) Obesity, autoimmunity, 
and double diabetes in youth. Diabetes Care 34 Suppl 2: S166-170.
11. Buchanan TA, Xiang A, Kjos SL, Watanabe R (2007) What is gestational 
diabetes? Diabetes Care 30 Suppl 2: S105-111.
12. Wong V (2014) Diagnosis of gestational diabetes mellitus: Where are we 
at?Int J Diabetes Clin Diagn 1: 104.
13. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of 
diabetes: estimates for the year 2000 and projections for 2030. Diabetes 
Care 27: 1047-1053.
14. Gerland P, Raftery AE, Sevcikova H, Li N, Gu D, et al. (2014) World 
population stabilization unlikely this century. Science 346: 234-237.
15. Farret, Lugo-Garcia L, Galtier F, Petit P (2005) Pharmacological 
interventions that directly stimulate or modulate insulin secretion from 
pancreatic beta-cell: implications for the treatment of type 2 diabetes. 
Fundam Clin Pharmacol 19: 647- 656.
Citation: Kov´acs L, Eigner G (2015) System Engineering Approach of Diabetes Treatment. Int J Diabetes Clin Diagn  3: 116. doi: http://dx.doi.org/10.15344/2394-
1499/2016/116
Int J Diabetes Clin Diagn                                                                                                                                                                                      IJDCD, an open access journal   
ISSN: 2394-1499                                                                                                                                                                                                     Volume 3. 2016. 116                                   
       Page 5 of 6
16. ElEssawy B, Li XC (2015) Type 1 diabetes and T regulatory cells. 
Pharmacol Res 98: 22-30.
17. Potter KJ, Westwell-Roper CY, Klimek-Abercrombie AM, Warnock GL, 
Verchere CB (2014) Death and dysfunction of transplanted Î²-cells: lessons 
learned from type 2 diabetes? Diabetes 63: 12-19.
18. Robertson R,  Davis C,  Larsen J, Stratta R,  Sutherland D (2000) Pancreas 
and islet transplantation for patients with diabetes mellitus (technical 
review). Diabetes Care 23: 112-116.
19. Chee F, Fernando T (2007) Closed-Loop Control of Blood Glucose. 1st ed. 
Berlin Germany: Springer-Verlag.
20. Cobelli C, Renard E, Kovatchev B (2011) Artificial pancreas: past, present, 
future. Diabetes 60: 2672-2682.
21. Shah VN, Shoskes A, Tawfik B, Garg SK (2014) Closed-loop system in the 
management of diabetes: past, present, and future. Diabetes Technol Ther 
16: 477-490.
22. Al-Tabakha MM, Arida AI (2008) Recent challenges in insulin delivery 
systems: a review. Indian J Pharm Sci 70: 278-286.
23. Sherr J, Tamborlane W (2008) Past, present, and future if insulin pump 
therapy: A better shot at diabetes control. Mt Sinai J Med 75: 352-361.
24. Valla V (2010) Therapeutics of diabetes mellitus: focus on insulin analogues 
and insulin pumps. Exp Diabetes Res 2010: 178372.
25. Medtronic (2012) Mini Med R 530G System User Guide. Northridge, USA: 
Medtronic MiniMed.
26. Tandem (2012) t:slimR Insulin Pump User Guide. San Diego, USA: Tandem 
Diabetes Care.
27. Roche (2015) Accu-ChekR Combo Training Handbook. Basel Switzerland: 
Roche.
28. Eigner G, Sas P, Kov´acs L (2014) Continuous glucose monitoring systems 
in the service of artificial pancreas,in SACI 2014-IEEE 9th International 
Symposium on Applied Computational Intelligence and Informatics. A. 
Szak´al, Ed. IEEE Hungary Section- 117-122.
29. Mayo Clinic’s Research Magazine (2011) Can an ’artificial pancreas’ 
normalize type 1 diabetes? July 2011.
30. Kamath S (2013) Model based simulation for type 1 diabetes patients. 
Asian Am J Chem 1: 11-19.
31. Ramprasad Y, Rangaiah G, Lakshminarayanan S (2004) Robust pid 
controller for blood glucose regulation in type i diabetics. Ind Eng Chem 
Res 43: 8257-8268.
32. Marchetti G, Barolo M, Jovanovic L, Zisser H, Seborg DE (2008) An 
improved PID switching control strategy for type 1 diabetes. IEEE Trans 
Biomed Eng 55: 857-865.
33. Kirchsteiger H, del Re L (2013) Robust tube-based predictive control of 
blood glucose concentration in type 1 diabetes. in 2013 IEEE 52nd Annual 
Conference on Decision and Control (CDC). IEEE 2084-2089.
34. Maxime P, Gueguen H, Belmiloudi A (2013) A robust receding horizon 
control approach to artificial glucose control for type 1 diabetes. Nonlin 
Contr Sys 9:833-838.
35. Hovorka R, Canonico V, Chassin L, Haueter U, Massi-Benedetti M, et 
al. (2004) Nonlinear model predictive control of glucose concentration in 
subjects with type 1 diabetes. Physiol Meas 25: 905-920.
36. Kirchsteiger H, del Re L Nonlinear model predictive control with moving 
horizon state and disturbance estimation - application to the normalization 
of blood glucose in the critically ill. in Proceedings of the 17th World 
Congress The International Federation of Automatic Control. IFAC 17: 
9069-9074.
37. Atlas E, Nimri R, Miller S, Grunberg EA, Phillip M (2010) MD-logic artificial 
pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 
33: 1072-1076.
38. Herrero P, Georgiou P, Oliver N, Johnston DG, Toumazou C (2012) A 
bio-inspired glucose controller based on pancreatic β -cell physiology. J 
Diabetes Scien Technol 6: 606-616.
39. Osgouie K, Azizi A (2010) Optimizing fuzzy logic controller for diabetes 
type i by genetic algorithm, in 2010 The 2nd International Conference on 
Computer and Automation Engineering (ICCAE). ICCAE 4-8.
40. Kov´acs L, Szalay P, Alm´assy Z, Barkai L (2013) Applicability results of a 
nonlinear model-based robust blood glucose control algorithm,J Diabetes 
Scien Technol 7: 708-716.
41. Kov´acs L, Szalay P, Beny´o B, Chase G  Applicability results of a nonlinear 
model-based robust blood glucose control algorithm. J Diabetes Scien 
Technol 7: 708-716.
42. Kovács L, Benyó B, Bokor J, Benyó Z (2011) Induced Lâ‚‚-norm minimization 
of glucose-insulin system for Type I diabetic patients. Comput Methods 
Programs Biomed 102: 105-118.
43. Szalay P, Eigner G, Kozlovszky M, Rudas I, Kovacs L (2013) The 
significance of LPV modeling of a widely used T1DM model. Conf Proc 
IEEE Eng Med Biol Soc 2013: 3531-3534.
44. Szalay P, Eigner G, Kov´acs L (2014) Linear matrix inequality-based robust 
controller design for type-1 diabetes model. in IFAC 2014-19th World 
Congress of The International Federation of Automatic Control 9247-9252.
45. LatafaT P, Palumbo P, Pepe P, Kov´acs L, Panunzi S, et al. (2015) An lmi-
based controller for the glucose-insulin system. in 2015 European Control 
Conference (ECC). IFAC 7-12.
46. Takarics B, Baranyi P (2015) Tp model-based robust stabilization of the 
3 degrees-of-freedom aeroelastic wing section. ACTA Polytech Hung 12: 
209-228.
47. Takarics B, baranyi P (2015) Friction compensation in tp model form - 
aeroelastic wing as an example system. ACTA Polytech Hung 12: 127-145.
48. Galambos P, Kuti J, Baranyi P (2013) On the tensor product based 
qlpv modeling of bio-inspired dynamic processes. in 2013 IEEE 17th 
International Conference on Intelligent Engineering Systems (INES). IEEE 
Hungary Section 79-84.
49. B´atora V, T´arnik M, Murgas J, Schmidt S, Nogaard K, et al. (2015) 
Bihormonal control of blood glucose in people with type 1 diabetes. in 2015 
European Control Conference (ECC). IFAC 25-30.
50. Gingras V, Rabasa-Lhoret R, Messier V, Ladouceur M, Legault L, et 
al. (2015)  Efficacy of dual-hormone artificial pancreas to alleviate the 
carbohydrate-counting burden of type 1 diabetes: A randomized crossover 
trial. Diabetes Metab 3636.
51. Bergman RN, Urquhart J (1971) The pilot gland approach to the study of 
insulin secretory dynamics. Recent Prog Horm Res 27: 583-605 passim.
52. Bergman RN, Ider YZ, Bowden CR, Cobelli C (1979) Quantitative estimation 
of insulin sensitivity. Am J Physiol 236: E667-677.
53. Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors 
controlling glucose tolerance in man: measurement of insulin sensitivity 
and beta-cell glucose sensitivity from the response to intravenous glucose. 
J Clin Invest 68: 1456-1467.
54. Toffolo G, Bergman R, Finegood D, Bowden C, Cobelli C (1980) Quantitative 
estimation of beta cell sensitivity to glucose in the intact organism - a 
minimal model of insulin kinetics in the dog. Diabetes 29: 979-990.
55. Wong X, Chase J, Shaw G, Hann C, Lin J, et al. (2005)  Comparison of 
adaptive and sliding-scale glycaemic control in critical care and the impact 
of nutritional inputs. In 12th International Conference On Biomedical 
Engineering 4.
56. Wong X, Chase J, Shaw G, Hanna C, Lotz T, et al. (2006) Model predictive 
glycaemic regulation in critical illness using insulin and nutrition input: A 
pilot study. Med Eng Phys 28: 665-681.
57. Pielmeier U, Andreassen S, Nielsen B, Chase J, et al. (2010) A simulation 
model of insulin saturation and glucose balance for glycaemic control in icu 
patients. Comput Methods Biomec 97: 211-2 22.
Citation: Kov´acs L, Eigner G (2015) System Engineering Approach of Diabetes Treatment. Int J Diabetes Clin Diagn  3: 116. doi: http://dx.doi.org/10.15344/2394-
1499/2016/116
Int J Diabetes Clin Diagn                                                                                                                                                                                      IJDCD, an open access journal   
ISSN: 2394-1499                                                                                                                                                                                                     Volume 3. 2016. 116                                   
       Page 6 of 6
58. Chase JG, Suhaimi F, Penning S, Preiser JC, Le Compte AJ, et al. (2010) 
Validation of a model-based virtual trials method for tight glycemic control 
in intensive care. Biomed Eng Online 9: 84.
59. Dickson J, Hewett J, Gunn C, Lynn A, Shaw G, et al. (2013) On the 
problem of patient-specific endogenous glucose production in neonates on 
stochastic targeted glycemic control. J Diabetes Sci Technol 7: 913-927.
60. Stewart K, Pretty C, Tomlinson H, Fisk L, Shaw G,et al. (2015) Stochastic 
model predictive (stomp) glycaemic control for the intensive care unit: 
Development and virtual trial validation. Biomed Signal Proces 16: 61-67.
61. Dalla Man C, Rizza RA, Cobelli C (2006) Mixed meal simulation model 
of glucose-insulin system. Conf Proc IEEE Eng Med Biol Soc 1: 307-310.
62. Magni L, Raimondo DM, Bossi L, Man CD, De Nicolao G, et al. (2007) 
Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci 
Technol 1: 804-812.
63. Man CD, Micheletto F, Lv D, Breton M, Kovatchev B, et al. (2014) The 
UVA/PADOVA Type 1 Diabetes Simulator: New Features. J Diabetes Sci 
Technol 8: 26-34.
64. Hovorka R, Canonico V, Chassin LJ, Haueter U, Massi-Benedetti M, et 
al. (2004) Nonlinear model predictive control of glucose concentration in 
subjects with type 1 diabetes. Physiol Meas 25: 905-920.
65. Wilinska M, Chassin L, Acerini C, Allen J, et al. (2010) Simulation 
environment to evaluate closed-loop insulin delivery systems in type 1 
diabetes. J Diabetes Scien Technol 4: 132-144.
66. Sorensen J (1985) A physiological model of glucose metabolism in man 
and it use to design and access improved insulin therapies for diabetes. 
Ph.D. dissertation, Department of Chemical Engineering, Massachusetts 
Institute of Technology.
67. Skjaervold N, stling DO, Hjelme D, Spigset O, Lyng O, et al. (2013) Blood 
glucose control using a novel continuous blood glucose monitor and 
repetitive intravenous insulin boluses: Exploiting natural insulin pulsatility 
as a principle for a future artificial pancreas. Int J Endocrin 1-6.
68. De Gaetano A, Hardy T, Beck B, Abu-Raddad E, Palumbo P, et al. (2008) 
Mathematical models of diabetes progression. Am J Physiol Endocrinol 
Metab 295: E1462-1479.
69. Kong J, Kumar S, Palumbo P (2014) Dde models of the glucoseinsulin 
system: a useful tool for the artificial pancreas,in Proceedings in 
Mathematics and Statistics, G. Ajomne-Marsan and M. Delitala, Eds. 
Springer, 2014, ch. Managing Complexity, Reducing Perplexity in Biological 
Systems 109-117.
70. Zimei W (2013) Mathematical models with delays for glucose-insulin 
regulation and applications in artificial pancreas,Ph.D. dissertation, Doctor 
of Philosophy Department of Mechanical Engineering, National University 
of Singapore.
71. Palumbo P, Ditlevsen S, Bertuzzi A, De Gaetano A (2013) Mathematical 
modeling of the glucose-insulin system: a review. Math Biosci 244: 69-81.
72. Arleth T, Andreassen S, Orsini-Federici M, Timi A, Massi Benedetti M (2000) 
A model of glucose absorption from mixed meals,in Modelling and control 
in biomedical systems 2000 (including biological systems): a proceedings 
volume from the 4th IFAC Symposium, E. Carson and E. Salzsieder, Eds. 
Pergamon Press 307-312.
73. Arleth T, Andreassen S, Orsini-Federici M, Timi A () Optimisation of a model 
of glucose absorption from mixed meals. Alborg Uni 1-28.
74. De Gaetano A, Panunzi S, Matone A, Samson A, Vrbikova J, et al. (2013) 
Routine ogtt: A robust model including incretin effect for precise identification 
of insulin sensitivity and secretion in a single individual PLoS ONE 8.
75. De Geatano A, Hardy T, Beck B, Abu-Raddad E, Palumbo P, et al. (2006) 
System model of oral glucose absorption: Validation on gold standard data. 
IEEE T Bio-Med Eng 53: 2472-2478.
76. Dalla Man C, Toffolo G, Basu R, Rizza RA, Cobelli C (2006) A model of 
glucose production during a meal. Conf Proc IEEE Eng Med Biol Soc 1: 
5647-5650.
77. Eigner G, Kov´acs L (2014) Realization methods of continuous glucose 
monitoring systems. Scientific Bulletin of the Politechnica University of 
Timisoara, Romania. 59: 175-183.
78. Scuffi C, Lucarelli F, Valgimigli F (2012) Minimizing the impact of time 
lag variability on accuracy evaluation of continuous glucose monitoring 
systems. J Diabetes Scien Technol 6: 1383-1391.
79. Wang X, Mdingi C, DeHennis A, Colvin A (2012) Algorithm for an implantable 
fluorescence based glucose sensor. In 34th Annual International 
Conference of the IEEE Engineering in Medicine and Biology Society. IEEE 
EMBS 3492-3495.
80. Schiavon M, Dalla Man C, Dube S, Slama M, Kudva YC, et al. (2015) 
Modeling Plasma-to-Interstitium Glucose Kinetics from Multitracer Plasma 
and Microdialysis Data. Diabetes Technol Ther 17: 825-831.
